@article {PavordP1593, author = {Ian Pavord and Anthony De Soyza and J. Stuart Elborn and David Smith and Heather Wray and Margareta Puu and Bengt Larsson and Robert Stockley}, title = {Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis}, volume = {42}, number = {Suppl 57}, elocation-id = {P1593}, year = {2013}, publisher = {European Respiratory Society}, abstract = {Rationale:CXCR2 antagonist AZD5069 may be useful for neutrophilic airway diseases, including bronchiectasis. This early phase study assessed the effects of AZD5069 on sputum neutrophil numbers, a range of biomarkers, other variables and safety in bronchiectasis patients (pts).Methods:Pts with radiological bronchiectasis entered a randomised, double-blind, parallel-group, multicentre study (NCT01255592) of oral AZD5069 80 mg (n=26) or placebo (PBO; n=26) twice daily for 4 weeks. The primary outcome was relative change in absolute sputum neutrophil count.Results:Table 1 summarises baseline demographics and effects of treatment. AZD5069 reduced neutrophil counts by 69\% vs PBO (p=0.004). There were no clinically relevant effects on secondary variables. Biomarkers (sputum IL-6, GRO-α; serum GRO-α, IL-1β, IL-8) increased with AZD5069 vs PBO (p<=0.001), but this was not considered to affect AZD5069 efficacy (since effect on the primary target was confirmed by reduced sputum neutrophils). More pts receiving AZD5069 reported adverse events (23 vs 16). Incidence of infections was similar with AZD5069 and PBO but infections led to more study discontinuations with AZD5069 (4 vs 0).View this table:Conclusions:AZD5069 resulted in a statistically significant reduction in sputum neutrophils vs PBO. Clinical status was not improved in this short-term study.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/42/Suppl_57/P1593}, eprint = {https://erj.ersjournals.com/content/42/Suppl_57/P1593.full.pdf}, journal = {European Respiratory Journal} }